<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01780246</url>
  </required_header>
  <id_info>
    <org_study_id>ISIS 396443-CS10</org_study_id>
    <nct_id>NCT01780246</nct_id>
  </id_info>
  <brief_title>An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy Who Previously Participated in ISIS 396443-CS1 (NCT01494701)</brief_title>
  <official_title>An Open-label Study to Assess the Safety and Tolerability of a Single Intrathecal Dose of ISIS 396443 in Patients With Spinal Muscular Atrophy Who Previously Participated in ISIS 396443-CS1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to examine the safety and tolerability of nusinersen&#xD;
      (ISIS 396443) administered intrathecally to participants with Spinal Muscular Atrophy (SMA)&#xD;
      who previously participated in ISIS 396443-CS1 (NCT02865109). The secondary objective was to&#xD;
      examine the plasma pharmacokinetics of a single dose of ISIS 396443 administered&#xD;
      intrathecally to participants with SMA who previously participated in ISIS 396443-CS1.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was conducted and the protocol was registered by Ionis Pharmaceuticals, Inc.&#xD;
&#xD;
      In August 2016, sponsorship of the trial was transferred to Biogen.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 31, 2013</start_date>
  <completion_date type="Actual">February 28, 2014</completion_date>
  <primary_completion_date type="Actual">February 28, 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants that experience Adverse Events (AEs) and Serious Adverse Events</measure>
    <time_frame>Up to 24 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant neurological examination abnormalities</measure>
    <time_frame>Up tp 24 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant vital sign abnormalities</measure>
    <time_frame>Up to 24 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant physical examination abnormalities</measure>
    <time_frame>Up to 24 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant weight abnormalities</measure>
    <time_frame>Up to 24 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant laboratory parameters</measure>
    <time_frame>Up to 24 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant electrocardiograms (ECGs) abnormalities</measure>
    <time_frame>Up to 24 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who use concomitant medications</measure>
    <time_frame>Up to 24 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameters of nusinersen (ISIS 396443): Maximum observed plasma drug concentration (Cmax)</measure>
    <time_frame>Plasma at 1, 2, 4 and 6 hours after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of nusinersen: Time to reach maximum observed concentration (Tmax)</measure>
    <time_frame>Plasma at 1, 2, 4 and 6 hours after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of nusinersen: Area under the plasma concentrations time curve from the time of the intrathecal (IT) dose to the last collected sample (AUCinf)</measure>
    <time_frame>Plasma at 1, 2, 4 and 6 hours after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of nusinersen (ISIS 396443): Apparent terminal elimination half-life (t1/2), if possible</measure>
    <time_frame>Plasma at 1, 2, 4 and 6 hours after dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Spinal Muscular Atrophy</condition>
  <arm_group>
    <arm_group_label>nusinersen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nusinersen</intervention_name>
    <description>Administered by intrathecal (IT) injection</description>
    <arm_group_label>nusinersen</arm_group_label>
    <other_name>Sprinraza</other_name>
    <other_name>ISIS 396443</other_name>
    <other_name>IONIS-SMN Rx</other_name>
    <other_name>BIIB058</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Clinical signs attributable to Spinal Muscular Atrophy&#xD;
&#xD;
          -  Satisfactory completion of dosing and all study visits in ISIS 396443-CS1&#xD;
             (NCT01494701) with an acceptable safety profile, per Investigator judgement.&#xD;
&#xD;
          -  Able to complete all study procedures, measurements and visits and parent/participant&#xD;
             has adequately supportive psychosocial circumstances, in the opinion of the&#xD;
             investigator&#xD;
&#xD;
          -  Estimated life expectancy &gt; 2 years from Screening&#xD;
&#xD;
          -  Meets age-appropriate institutional criteria for use of anesthesia/sedation, if use is&#xD;
             planned for study procedure&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Have any new or worsening of existing condition which in the opinion of the&#xD;
             Investigator would make the participant unsuitable for enrollment, or could interfere&#xD;
             with the participant participating in or completing the study.&#xD;
&#xD;
          -  Dosing in ISIS 396443-CS1 (NCT01494701) within 270 days (9 months) of screening, or&#xD;
             longer ago than 450 days (15 months)&#xD;
&#xD;
          -  Dosing in ISIS 396443-CS2 (NCT01703988)&#xD;
&#xD;
          -  Hospitalization for surgery (i.e. scoliosis surgery) or pulmonary event within 2&#xD;
             months of screening or planned during the duration of the study&#xD;
&#xD;
          -  Presence of an untreated or inadequately treated active infection requiring systemic&#xD;
             antiviral or antimicrobial therapy any time during the screening period&#xD;
&#xD;
          -  Clinically significant abnormalities in hematology or clinical chemistry parameters&#xD;
&#xD;
          -  Treatment with investigational drug, biological agent, or device within 1-month of&#xD;
             Screening or 5 half-lives of study agent, whichever is longer. Treatment with&#xD;
             valproate or hydroxyurea within 1 months of screening. Any history of gene therapy or&#xD;
             cell transplantation&#xD;
&#xD;
        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center - Children's Medical Center Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah School of Medicine</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.curesma.org</url>
    <description>Cure SMA</description>
  </link>
  <link>
    <url>http://mda.org/disease/spinal-muscular-atrophy</url>
    <description>Muscular Dystrophy Association</description>
  </link>
  <link>
    <url>http://www.rarediseases.org</url>
    <description>National Organization for Rare Diseases</description>
  </link>
  <link>
    <url>http://clinicalresearch.biogen.com/Content/Studies/CS10%20Biogen.com%20Packet.pdf</url>
    <description>Clinical Study Report (CSR) Synopsis - a results summary</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 28, 2013</study_first_submitted>
  <study_first_submitted_qc>January 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2013</study_first_posted>
  <last_update_submitted>February 12, 2021</last_update_submitted>
  <last_update_submitted_qc>February 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Spinal Muscular Atrophy</keyword>
  <keyword>SMA</keyword>
  <keyword>SMN</keyword>
  <keyword>SMNRx</keyword>
  <keyword>ISIS-SMNRx</keyword>
  <keyword>ISIS 396443</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Muscular Atrophy, Spinal</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

